drugset / Trial / NCT04231370
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with lenalidomide in the treatment of Relapsed/Refractory NK/T-cell lymphoma patients who failed pegaspargase-based regimens.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2022-02-28
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |